|
|
 Previous Article | Table of Contents | Next Article 
Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven
Selection
Vittorio Perfetti,
Paola Ubbiali,
Maurizio Colli Vignarelli,
Marta Diegoli,
Roberta Fasani,
Monica Stoppini,
Antonella Lisa,
Palma Mangione,
Laura Obici,
Eloisa Arbustini, and
Giampaolo Merlini
From the Research Laboratories of Biotechnology and Organ
Transplantation, Clinical Immunology Unit, the Department of Internal
Medicine, Section of Internal Medicine and Medical
Oncology, and the Institutes of Human
Pathology, Biochemistry, and
CNR-IGBE, University of Pavia-IRCCS Policlinico S. Matteo,
Pavia, Italy.
AL amyloidosis is characterized by fibrillar tissue deposits
(amyloid) composed of monoclonal light chains secreted by small numbers
of indolent bone marrow plasma cells whose ontogenesis is unknown. To
address this issue and to provide insights into the processes that
accompanied pathogenic light chain formation, we isolated the complete
variable (V) regions of 14 light (VL) and 3 heavy (VH) chains secreted
by amyloid clones at diagnosis (10 Bence Jones and 4 with complete Igs,
9  and 5  ) by using an inverse polymerase chain reaction-based
approach free of primer-induced biases. Amyloid V regions were found to
be highly mutated compared with the closest germline genes in the
databases or those isolated from the patients' DNA, and mutations were
not associated with intraclonal diversification. Apparently high usage
of the III family germline gene V III.1 was observed (4 of 9 light chains). Analysis of the nature and distribution of somatic
mutations in amyloid V regions showed that there was statistical
evidence of antigen selection in 8 of 14 clones (7 in VL and 1 in VH).
These results indicate that a substantial proportion of the amyloid clones developed from B cells selected for improved antigen binding properties and that pathogenic light chains show evidence of this selection.
Blood, Vol. 91 No. 8 (April 15), 1998:
pp. 2948-2954
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Sitia, G. Palladini, and G. Merlini
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Haematologica,
October 1, 2007;
92(10):
1302 - 1307.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Merlini and V. Bellotti
Molecular Mechanisms of Amyloidosis
N. Engl. J. Med.,
August 7, 2003;
349(6):
583 - 596.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Abraham, S. M. Geyer, T. L. Price-Troska, C. Allmer, R. A. Kyle, M. A. Gertz, and R. Fonseca
Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL)
Blood,
May 15, 2003;
101(10):
3801 - 3807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Perfetti, S. Casarini, G. Palladini, M. C. Vignarelli, C. Klersy, M. Diegoli, E. Ascari, and G. Merlini
Analysis of Vlambda -Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment
Blood,
July 18, 2002;
100(3):
948 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Hayman, R. J. Bailey, S. M. Jalal, G. J. Ahmann, A. Dispenzieri, M. A. Gertz, P. R. Greipp, R. A. Kyle, M. Q. Lacy, S. V. Rajkumar, et al.
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis
Blood,
October 1, 2001;
98(7):
2266 - 2268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Smith and S. E. Radford
Role of the single disulphide bond of {beta}2-microglobulin in amyloidosis in vitro
Protein Sci.,
September 1, 2001;
10(9):
1775 - 1784.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
